Biological bases of cancer: a proposal of minimum contents for health schools
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
The publication is free and its contents are distributed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International licence (CC BY-NC-ND 4.0). The rights of the works published in this journal are property of the author and they are free to distribute and disseminate the same sources as long as he correctly cites the font of publication, these acts are not for commercial purposes and no derivative works are generated.
Main Article Content
Abstract
Cancer constitutes the second most common cause of death worldwide and is expected to become the leading one, even above cardiovascular diseases. The understanding of the cellular and molecular basis of cancer has led not only to the proper development of chemotherapy but also of target therapies. Although these advances are related with improved survival rates among cancer patients, it has poorly impacted its incidences. In this regard, the lack of knowledge regarding the impact that the several carcinogenic factors and their interactions have on different types of cancers may explain at least in part the difficulties to reduce incidence rates. However, is worth noticing that in several health schools of Chilean universities, cancer does not constitute a formal course, being only partially approached during other courses, such as cell biology, internal medicine, and surgery. Thus, the aim of our work is to provide students a simple and resumed manuscript about essential topics necessary to understand the biological basis of cancer. First, the reader will find some fundamentals about human biology including the cell cycle and the central dogma of molecular biology, which offers an overview of the physiological mechanisms leading to malignant neoplasia. Then, we will provide current definitions of neoplasia, benign and malignant tumors are provided. Finally, the different stages of tumor progression will be approached to allow the understanding of cancer development. These stages include (i) initiation, (ii) promotion, and (iii) progression. For the last one, metastasis, angiogenesis, extracellular matrix degradation, migration, and immune evasion will also be addressed. This work will not consider the metabolic hypothesis of cancer.
References
Alberts B. et al. (2007). Molecular Biology of the Cell, 5th ed., n.d.
Alvarez, C., Tapia, T., Perez-Moreno, E., Gajardo-Meneses, P., Ruiz, C., Rios, M., Missarelli, C., Silva, M., Cruz, A., Matamala, L., Carvajal-Carmona, L., Camus, M., Carvallo, P., 2017. BRCA1 and BRCA2 founder mutations account for 78% of germline carriers among hereditary breast cancer families in Chile. Oncotarget 8, 74233–74243.
Arvind Babu, R.S., Ramana Reddy, B. V., Anuradha, C.H., 2014. Histogenetic concepts, terminology and categorization of biphasic tumours of the oral and maxillofacial region. J. Clin. Diagnostic Res.
Barton, M.B., Bell, P., Sabesan, S., Koczwara, B., 2006. What should doctors know about cancer? Undergraduate medical education from a societal perspective. Lancet Oncol.
Botelho, M.C., Teixeira, J.P., Oliveira, P.A., 2014. Carcinogenesis. Encycl. Toxicol. Third Ed. 53, 713–729.
Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R.L., Torre, L.A., Jemal, A., 2018. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA. Cancer J. Clin. 68, 394–424.
Croce, C.M., 2008. Oncogenes and Cancer. N. Engl. J. Med. 358, 502–511.
Deeks, S.G., Overbaugh, J., Phillips, A., Buchbinder, S., 2015. HIV infection. Nat. Rev. Dis. Prim. 1, 1–22.
Dorsam, R.T., Gutkind, J.S., 2007. G-protein-coupled receptors and cancer. Nat. Rev. Cancer.
Duncan, L., Shen, H., Gelaye, B., Meijsen, J., Ressler, K., Feldman, M., Peterson, R., Domingue, B., 2019. Analysis of polygenic risk score usage and performance in diverse human populations. Nat. Commun. 10.
Frade, J.M., Ovejero-Benito, M.C., 2015. Neuronal cell cycle: the neuron itself and its circumstances The Cell Cycle: A Rapid Overview. Cell Cycle 14, 712–720.
Hanahan, D., Weinberg, R.A., 2011. Hallmarks of cancer: The next generation. Cell 144, 646–674.
Janku, F., Yap, T.A., Meric-Bernstam, F., 2018. Targeting the PI3K pathway in cancer: Are we making headway? Nat. Rev. Clin. Oncol.
Johnson, D.E., O’Keefe, R.A., Grandis, J.R., 2018. Targeting the IL-6/JAK/STAT3 signalling axis in cancer. Nat. Rev. Clin. Oncol.
Kim, S.Y., 2018. Cancer energy metabolism: Shutting power off cancer factory. Biomol. Ther.
Levine, A.J., Oren, M., 2009. The first 30 years of p53: Growing ever more complex. Nat. Rev. Cancer.
Ley Nacional de Cáncer (n°21258) MINSAL, n.d.
Lu, Y., Chan, Y.T., Tan, H.Y., Li, S., Wang, N., Feng, Y., 2020. Epigenetic regulation in human cancer: The potential role of epi-drug in cancer therapy. Mol. Cancer.
Malumbres, M., Barbacid, M., 2003. RAS oncogenes: The first 30 years. Nat. Rev. Cancer.
Meacham, C.E., Morrison, S.J., 2013. Tumour heterogeneity and cancer cell plasticity. Nature.
Neeley, B.C., Golden, D.W., Brower, J. V., Braunstein, S.E., Hirsch, A.E., Mattes, M.D., 2019. Student Perspectives on Oncology Curricula at United States Medical Schools. J. Cancer Educ. 34, 56–58.
Paul, C.D., Mistriotis, P., Konstantopoulos, K., 2017. Cancer cell motility: Lessons from migration in confined spaces. Nat. Rev. Cancer.
Pickup, M., Novitskiy, S., Moses, H.L., 2013. The roles of TGFβ in the tumour microenvironment. Nat. Rev. Cancer.
Poltavets, V., Kochetkova, M., Pitson, S.M., Samuel, M.S., 2018. The role of the extracellular matrix and its molecular and cellular regulators in cancer cell plasticity. Front. Oncol.
Qing, T., Mohsen, H., Marczyk, M., Ye, Y., O’Meara, T., Zhao, H., Townsend, J.P., Gerstein, M., Hatzis, C., Kluger, Y., Pusztai, L., 2020. Germline variant burden in cancer genes correlates with age at diagnosis and somatic mutation burden. Nat. Commun. 11, 1–8.
Robbins and Cotran. (2008). Pathologic Basis of disease. Chapter Neoplasia. Ed.Elsevier Saunders., n.d.
Samah, A.A., Fauzi, M.F.A., Mansor, S., 2017. Classification of benign and malignant tumors in histopathology images. In: Proceedings of the 2017 IEEE International Conference on Signal and Image Processing Applications, ICSIPA 2017. Institute of Electrical and Electronics Engineers Inc., pp. 102–106.
Series y Gráficos de Mortalidad - DEIS [WWW Document], n.d. URL http://www.deis.cl/series-y-graficos-de-mortalidad/ (accessed 1.11.19).
Sherr, C.J., 2004. Principles of Tumor Suppression. Cell.
Vogelstein, B., Papadopoulos, N., Velculescu, V.E., Zhou, S., Diaz, L.A., Kinzler, K.W., 2013. Cancer genome landscapes. Science (80-. ).
Waldman, A.D., Fritz, J.M., Lenardo, M.J., 2020. A guide to cancer immunotherapy: from T cell basic science to clinical practice. Nat. Rev. Immunol.
Weis, S.M., Cheresh, D.A., 2011. Tumor angiogenesis: Molecular pathways and therapeutic targets. Nat. Med.
Witsch, E., Sela, M., Yarden, Y., 2010. Roles for Growth Factors in Cancer Progression. Physiology.
Yan, M., Schwaederle, M., Arguello, D., Millis, S.Z., Gatalica, Z., Kurzrock, R., 2015. HER2 expression status in diverse cancers: review of results from 37,992 patients. Cancer Metastasis Rev. 34, 157–164.